Sanofi vet Kather­ine Bowdish named CEO of PIC Ther­a­peu­tics; As the world Terns: Liv­er dis­ease biotech makes ex­ec­u­tive changes

Kather­ine Bowdish

PIC Ther­a­peu­tics hasn’t raised much mon­ey, yet. But the fledg­ling biotech has at­tract­ed a high-pro­file play­er to the helm.

The Boston-based biotech has hand­ed the reins to Kather­ine Bowdish as its pres­i­dent and CEO. Bowdish will al­so join the board of di­rec­tors of PIC. Bowdish joins from Sanofi where she served as VP and head of R&D strat­e­gy, as well as help­ing launch and lead Sanofi Sun­rise, a ven­ture in­vest­ment and part­ner­ing ve­hi­cle at Sanofi. Be­fore that, Bowdish held sev­er­al ex­ec roles at Per­me­on Bi­o­log­ics, Anaphore, Alex­ion Phar­ma­ceu­ti­cals and Pro­li­faron (ac­quired by Alex­ion).

PIC, in its own words, is fo­cused on trans­form­ing the treat­ment of can­cer through the se­lec­tive mod­u­la­tion of onco­gene trans­la­tion, which you can think more broad­ly about as con­trol­ling the ex­pres­sion of large banks of genes at a time in or­der to si­mul­ta­ne­ous­ly mod­u­late mul­ti­ple onco­genic dri­vers — a very am­bi­tious goal for a com­pa­ny that just raised a $5 mil­lion seed round.

Back in April Ad­vent Life Sci­ences led the launch round, with Be­lin­da Ter­meer, wid­ow of leg­endary Gen­zyme CEO Hen­ri Ter­meer, as well as “sev­er­al bio­phar­ma­ceu­ti­cal in­dus­try ex­ec­u­tives and oth­er in­di­vid­ual in­vestors” chip­ping in. We’re like­ly to hear more on that score in the not-too-dis­tant fu­ture.

Senthil Sun­daram

→ The C-suite has shuf­fled con­sid­er­ably at liv­er dis­ease-fo­cused Terns Phar­ma­ceu­ti­cals out of Fos­ter City, CA. Senthil Sun­daram now as­sumes the CEO post, re­plac­ing Wei­dong Zhong, who was at the helm since Terns was found­ed and is now mov­ing in­to two new roles: CSO and chair­man of the board. Sun­daram makes his way to Terns af­ter 2 years as CFO of Night­star Ther­a­peu­tics, which would lat­er be ac­quired by Bio­gen. He was al­so VP and head of busi­ness de­vel­op­ment at NASH play­er In­ter­cept af­ter 13 years in in­vest­ment bank­ing.

Else­where at Terns, Erin Quirk has added pres­i­dent to her CMO ti­tle and Mark Vi­g­no­la is their new CFO. A for­mer clin­i­cal re­search ex­ec at Gilead and Mer­ck, Quirk has been CMO since Jan­u­ary 2019. Vi­g­no­la comes to Terns from his CFO gig at Ap­plied Ther­a­peu­tics and, like Sun­daram, was an ex­ec at In­ter­cept.

→ There’s a change at the top at Is­raeli-based En­tera Bio, which fo­cus­es on oral­ly-de­liv­ered macro­mol­e­cule ther­a­pies, with Sanofi vet Roger Garceau get­ting the call as in­ter­im CEO af­ter Adam Gri­d­ley re­signed “to pur­sue an­oth­er op­por­tu­ni­ty.” Garceau, En­tera’s chief de­vel­op­ment ad­vi­sor since De­cem­ber 2016, will al­so con­tin­ue as a di­rec­tor. Pri­or to join­ing the board at En­tera in March 2016, he was CMO and EVP of R&D at NPS Phar­ma­ceu­ti­cals. Garceau filled sev­er­al ex­ec­u­tive roles at Sanofi, in­clud­ing VP of US new prod­uct mar­ket­ing.

Chris­t­ian Hen­ry

→ Men­lo Park, CA gene se­quenc­ing com­pa­ny Pa­cif­ic Bio­sciences, which Il­lu­mi­na at­tempt­ed to buy out un­til the deal fiz­zled at the start of this year, has cho­sen Chris­t­ian Hen­ry to lead the way as pres­i­dent and CEO, ef­fec­tive next month. Michael Hunkapiller, who an­nounced his re­tire­ment in June, has been at the helm since 2012 and will be­come a se­nior fel­low fo­cused on tech­nol­o­gy de­vel­op­ment once Hen­ry takes over. Hen­ry has been on PacBio’s board of di­rec­tors since 2018 and board mem­ber John Mil­li­gan will suc­ceed him as chair­man of the board, where Hen­ry had served since March. Hen­ry spent 12 years at Il­lu­mi­na and was both their CCO and CFO at sep­a­rate junc­tures.

In oth­er PacBio news, Su­san Barnes has re­tired from her CFO post, as Ben Gong has been named to re­place her on an in­ter­im ba­sis. Gong has been at PacBio for the past decade as their VP, fi­nance and trea­sur­er.

Janet Ham­mond

Janet Ham­mond has been in­stalled in the new­ly-cre­at­ed po­si­tion of chief de­vel­op­ment of­fi­cer at Jean-Pierre Som­ma­dos­si’s vi­ral dis­ease com­pa­ny Atea Phar­ma­ceu­ti­cals, which threw their hats in the Covid-19 ring and scored a $215 mil­lion fi­nanc­ing round in May. An ex-SVP at Roche, Ham­mond comes over from Ab­b­Vie, where she was their VP, in­fec­tious dis­eases and gen­er­al med­i­cine. She’s al­so been CMO, SVP and head of med­ical af­fairs at Valeant Phar­ma­ceu­ti­cals.

→ Nor­we­gian hema­tol­ogy and on­col­o­gy play­er Nordic Nanovec­tor has se­cured Chris­tine Wilkin­son Blanc as their CMO a few months af­ter sev­er­al oth­er ex­ec­u­tive changes. Wilkin­son Blanc, who got her start at Roche as a clin­i­cal re­search physi­cian, had been med­ical di­rec­tor of PhiMedics for the last decade and, from 2013-16, was CMO of Psioxus Ther­a­peu­tics.

Punit Dhillon

→ Fo­cused on cannabi­noid-based ther­a­pies, Cal­i­for­nia-based Emer­ald Bio­science has changed CEOs, vault­ing for­mer On­coSec CEO Punit Dhillon to the top spot af­ter Bri­an Mur­phy re­signed both as CEO and a board mem­ber. Dhillon, who al­so co-found­ed On­coSec in 2011, had been Emer­ald’s chair­man and is their found­ing di­rec­tor. Be­fore his time at On­coSec, he was In­ovio’s VP of fi­nance and op­er­a­tions.

Col­lab­o­rat­ing with Roche on im­muno-on­col­o­gy ther­a­pies, with mile­stones po­ten­tial­ly to the tune of $1.7 bil­lion, Bi­cy­cle Ther­a­peu­tics has steered to­ward a new CMO with Do­minic Smethurst, who has his share of ex­pe­ri­ence in the same po­si­tion at sev­er­al oth­er biotechs. Smethurst heads to UK-based Bi­cy­cle af­ter a few months as in­ter­im CMO at Nordic Nanovec­tor. He briefly held the CMO post at BerGen­Bio, and be­fore that, had a 2-year tenure as CMO at Tusk Ther­a­peu­tics.

Gal­lia Levy

→ As not­ed ear­li­er in the week, Gal­lia Levy has left her post at Genen­tech to be­come CMO of Roche sub­sidiary Spark Ther­a­peu­tics, whose he­mo­phil­ia A gene ther­a­py SPK-8011 is one of four pro­grams in clin­i­cal tri­als. Levy led glob­al de­vel­op­ment on Hem­li­bra for he­mo­phil­ia A, and was al­so Genen­tech’s VP, prod­uct de­vel­op­ment and glob­al head of the rare blood dis­or­ders fran­chise.

Adri­an Hep­n­er has been tapped as CMO of Pharnext, a French drug de­vel­op­er fo­cused on neu­rode­gen­er­a­tive dis­eases us­ing ge­nomics da­ta and AI. Be­fore head­ing to Pharnext, Hep­n­er was EVP and CMO of Ea­gle Phar­ma­ceu­ti­cals from 2015-20, had a short stint at UCB at their se­nior med­ical di­rec­tor, and spent 6 years as a clin­i­cal re­search ex­ec at Avanir Phar­ma­ceu­ti­cals.

Wilco Groen­huy­sen

→ UK-based on­col­o­gy play­er Novo­cure, which re­ceived an FDA OK in May 2019 with its NovoT­TF-100L Sys­tem for ma­lig­nant pleur­al mesothe­lioma, has an­nounced a hand­ful of per­son­nel moves, ef­fec­tive Sept 1. Wilco Groen­huy­sen is tran­si­tion­ing to COO af­ter 8 years as Novo­cure’s CFO, and as a re­sult, Ash­ley Cor­do­va has been pro­mot­ed from SVP, fi­nance and in­vestor re­la­tions to the CFO post. Frank Leonard has al­so been pro­mot­ed to the new­ly-cre­at­ed chief de­vel­op­ment of­fi­cer po­si­tion, as the 10-year Novo­cure vet moves on up from his pre­vi­ous role as their SVP, cor­po­rate strat­e­gy and health pol­i­cy.

→ AAV-based gene ther­a­py com­pa­ny Stride­Bio, part­ner­ing with Sarep­ta on four cen­tral ner­vous sys­tem tar­gets, has brought on William Mon­tei­th to be their COO. A pre-Pfiz­er deal Wyeth Phar­ma­ceu­ti­cals vet and a Den­dreon ex­ec from 2009-15, Mon­tei­th heads over to Stride­Bio from Cel­lec­tis, where he spent the last year as EVP, tech­ni­cal op­er­a­tions.

→ Psy­che­del­ic-in­spired med­i­cine de­vel­op­er MindMed is ex­pand­ing its Eu­ro­pean hori­zons and has cho­sen Miri Halperin Wern­li to lead the clin­i­cal and sci­en­tif­ic team in Eu­rope as pres­i­dent. Halperin Wern­li, the co-founder of Aus­tralian med­ical cannabis com­pa­ny Cre­so Phar­ma, is an Acte­lion vet who was their VP, deputy head of glob­al clin­i­cal de­vel­op­ment and glob­al head, busi­ness & sci­ence af­fairs.

Ellen Lub­man

Ellen Lub­man is on board as CBO of Long­wood-backed Cam­bridge, MA on­col­o­gy play­er Were­wolf Ther­a­peu­tics, which launched in No­vem­ber with a $56 mil­lion Se­ries A round. A Bris­tol My­ers Squibb vet well versed in M&A, Lub­man leaves her CBO post at Im­pel Neu­roPhar­ma, a role she filled for near­ly 2 years. Be­fore that, she was at Al­ler­gan from 2014-18 as their VP, ex­ter­nal sci­ence and in­no­va­tion.

→ On the rec­om­men­da­tion of prin­ci­pal in­ves­ti­ga­tor Manuel Hi­dal­go, La­gu­na Hills, CA-based Phar­ma­Cyte has brought in José Igle­sias as a con­sult­ing CMO for a Phase IIb clin­i­cal tri­al in lo­cal­ly ad­vanced, in­op­er­a­ble pan­cre­at­ic can­cer (LAPC). Igle­sias, who helped de­vel­op Abrax­ane while he was with Abrax­is and Cel­gene, is the cur­rent CMO at Sen­ti Bio­sciences.

Roger Sawh­ney

Flag­ship biotech Omega Ther­a­peu­tics, which hauled in $85 mil­lion a cou­ple weeks ago with its am­bi­tion to cre­ate an epi­ge­net­ic pro­gram­ming plat­form for what CEO Ma­hesh Karande calls the “con­trol room of hu­man bi­ol­o­gy,” has snagged Roger Sawh­ney as CFO. A for­mer SVP and head of glob­al cor­po­rate strat­e­gy at No­var­tis, Sawh­ney was most re­cent­ly di­rec­tor of KKR and Co’s health­care in­vest­ment team in the Amer­i­c­as.

→ Try­ing to dig out from the mess of their con­tro­ver­sy over busi­ness prac­tices, Ma­ri­et­ta, GA-based wound care com­pa­ny MiMedX has ap­point­ed Robert Stein their EVP of R&D. Stein’s work in the area of R&D goes back 30 years when he was SVP of R&D and CSO of Lig­and Phar­ma­ceu­ti­cals and lat­er at DuPont-Mer­ck Phar­ma­ceu­ti­cals. The ex-pres­i­dent and CSO of In­cyte and the ex-CEO at KineMed, Stein’s most re­cent ex­ec­u­tive gig in R&D was at Agenus.

Jeff Aronin’s Paragon Bio­sciences has tapped Keren­sa Jimenez as the new CEO of the com­pa­ny’s cap­i­tal mar­kets group, Paragon Health. Jimenez hops aboard the com­pa­ny from Oc­ta­gon Cap­i­tal Group, where she served as man­ag­ing di­rec­tor. In ad­di­tion, she’s was a di­rec­tor at Far­lie Turn­er.

Michael Levitz has as­sumed the CFO role at Bed­ford, MA or­tho­pe­dic med­i­cines biotech Ani­ka Ther­a­peu­tics. Pri­or to his ar­rival at Ani­ka, Levitz, who got his start at Arthur An­der­sen, had been SVP, CFO and trea­sur­er of two oth­er com­pa­nies: In­sulet Cor­po­ra­tion and Ana­log­ic Cor­po­ra­tion.

Az­iz Mot­ti­wala

→ Af­ter nam­ing Se­sha Neer­van­nan and Leo Green­stein last month to the COO and CFO posts, re­spec­tive­ly, Irvine, CA-based Tar­sus Phar­ma­ceu­ti­cals has fur­ther re­tooled its ex­ec­u­tive team with Az­iz Mot­ti­wala step­ping in as chief com­mer­cial of­fi­cer. Be­fore join­ing Tar­sus, whose lead drug TP-03 tar­gets the eye dis­ease De­mod­ex ble­phar­i­tis, Mot­ti­wala held the same role at Opi­ant Phar­ma­ceu­ti­cals and be­fore that was SVP and head of com­mer­cial at Avanir Phar­ma­ceu­ti­cals. He al­so spent more than a decade in nu­mer­ous po­si­tions at Al­ler­gan, leav­ing as their VP, US eye care mar­ket­ing.

Neil Bell has been se­lect­ed as chief de­vel­op­ment of­fi­cer at Avac­ta Life Sci­ences out of the UK. Bell start­ed out at Ei­sai and Pfiz­er be­fore as­sum­ing the role of ther­a­peu­tic area head for gas­troen­terol­o­gy and neu­rol­o­gy at Ipsen. Since then, he has led clin­i­cal op­er­a­tions at Te­va Phar­ma­ceu­ti­cals, Dai­ichi Sankyo and, most re­cent­ly, Au­to­lus.

Kevin Heller has signed on as EVP of R&D of Jasper Ther­a­peu­tics, which launched out of Stan­ford in De­cem­ber with a $50 mil­lion Se­ries A and is fo­cused on hematopoi­et­ic cell trans­plant ther­a­pies. Heller had pre­vi­ous­ly held the CMO post at NextCure and was al­so VP, head of an­ti­body clin­i­cal de­vel­op­ment for In­cyte. He’s al­so a Big Phar­ma vet, fill­ing on­col­o­gy roles at Bris­tol My­ers Squibb and As­traZeneca.

Man­asi Sin­ha Jaiman

→ Long­time stem cell play­er Vi­a­Cyte has snagged Man­asi Sin­ha Jaiman as VP, clin­i­cal de­vel­op­ment. Jaiman jumps from Co­v­ance Clin­i­cal De­vel­op­ment Ser­vices, where she served as se­nior med­ical di­rec­tor. She was al­so an at­tend­ing physi­cian at Har­vard Med­ical School and Mass­a­chu­setts Gen­er­al Hos­pi­tal.

→ Matthew Metivi­er has hopped aboard Is­raeli biotech Gami­da Cell as VP, hu­man re­sources. Metivi­er hails from Sage Ther­a­peu­tics, where he served in the same role. Pri­or to that, he held roles at In­fin­i­ty Phar­ma­ceu­ti­cals and Idenix Phar­ma­ceu­ti­cals (ac­quired by Mer­ck & Co).

→ Basel, Switzer­land biotech NBE-Ther­a­peu­tics just grabbed a new CEO in Bertrand Damour, and now Erich Schlick has been elect­ed chair­man of the board. Schlick is cur­rent­ly a gen­er­al part­ner and man­ag­ing di­rec­tor at Mu­nich VC Welling­ton Part­ners.

Suzanne Hoop­er

→ Bridge­Bio sub­sidiary Ei­dos Ther­a­peu­tics, which was near­ly re­claimed by Bridge­Bio un­til di­rec­tors spurned three of­fershas ap­point­ed Suzanne Sawochka Hoop­er and Duke Rohlen as in­de­pen­dent di­rec­tors to its board. Hoop­er is a for­mer EVP and gen­er­al coun­sel of Jazz Phar­ma­ceu­ti­cals, while Rohlen is CEO and man­ag­ing part­ner of Ajax Health.

→ Led by Kel­ly Mar­tin, Waltham, MA-based Ra­dius Health has giv­en Sean Mur­phy a spot on their board of di­rec­tors. Cur­rent­ly a board mem­ber at Po­sei­da Ther­a­peu­tics and Xenex Cor­po­ra­tion, Mur­phy was in cor­po­rate busi­ness de­vel­op­ment and M&A for more than 30 years at Ab­bott Lab­o­ra­to­ries.

John Jenk­ins

John Jenk­ins is now on the board of di­rec­tors at Proven­tion Bio. The cur­rent prin­ci­pal for drug and bi­o­log­i­cal prod­ucts at Green­leaf Health, the long­time FDA vet was di­rec­tor of the Of­fice of New Drugs at CDER from 2002-17.

Karuna Ther­a­peu­tics, fo­cused on neu­ropsy­chi­atric dis­or­ders, has wel­comed Lau­rie Ol­son to their board of di­rec­tors. A long­time Pfiz­er ex­ec, Ol­son was their EVP, strat­e­gy and com­mer­cial op­er­a­tions from 2012-18.

ZS Per­spec­tive: 3 Pre­dic­tions on the Fu­ture of Cell & Gene Ther­a­pies

The field of cell and gene therapies (C&GTs) has seen a renaissance, with first generation commercial therapies such as Kymriah, Yescarta, and Luxturna laying the groundwork for an incoming wave of potentially transformative C&GTs that aim to address diverse disease areas. With this renaissance comes several potential opportunities, of which we discuss three predictions below.

Allogenic Natural Killer (NK) Cells have the potential to displace current Cell Therapies in oncology if proven durable.

Despite being early in development, Allogenic NKs are proving to be an attractive new treatment paradigm in oncology. The question of durability of response with allogenic therapies is still an unknown. Fate Therapeutics’ recent phase 1 data for FT516 showed relatively quicker relapses vs already approved autologous CAR-Ts. However, other manufacturers, like Allogene for their allogenic CAR-T therapy ALLO-501A, are exploring novel lymphodepletion approaches to improve persistence of allogenic cells. Nevertheless, allogenic NKs demonstrate a strong value proposition relative to their T cell counterparts due to comparable response rates (so far) combined with the added advantage of a significantly safer AE profile. Specifically, little to no risk of graft versus host disease (GvHD), cytotoxic release syndrome (CRS), and neurotoxicity (NT) have been seen so far with allogenic NK cells (Fig. 1). In addition, being able to harness an allogenic cell source gives way to operational advantages as “off-the-shelf” products provide improved turnaround time (TAT), scalability, and potentially reduced cost. NKs are currently in development for a variety of overlapping hematological indications with chimeric antigen receptor T cells (CAR-Ts) today, and the question remains to what extent they will disrupt the current cell therapy landscape. Click for more details.

Hal Barron, Endpoints UKBIO20 (Jeff Rumans)

'Al­tos was re­al­ly a once-in-a-life­time op­por­tu­ni­ty': Hal Bar­ron re­flects on his big move

By all accounts, Hal Barron had one of the best jobs in Big Pharma R&D. He made more than $11 million in 2020, once again reaping more than his boss, Emma Walmsley, who always championed him at every opportunity. And he oversaw a global R&D effort that struck a variety of big-dollar deals for oncology, neurodegeneration and more.

Sure, the critics never let up about what they saw as a rather uninspiring late-stage pipeline, where the rubber hits the road in the Big Pharma world’s hunt for the next big near-term blockbuster, but the in-house reviews were stellar. And Barron was firmly focused on bringing up the success rate in clinical trials, holding out for the big rewards of moving the dial from an average 10% success rate to 20%.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Executive Director of the EMA Emer Cooke (AP Photo/Geert Vanden Wijngaert)

Eu­ro­pean Par­lia­ment signs off on strength­en­ing drug reg­u­la­tor's abil­i­ty to tack­le short­ages

The European Parliament on Thursday endorsed a plan to increase the powers of the European Medicines Agency, which will be better equipped to monitor and mitigate shortages of drugs and medical devices.

By a vote of 655 to 31, parliament signed off on a provisional agreement reached with the European Council from last October, in which the EMA will create two shortage steering groups (one for drugs, the other for devices), a new European Shortages Monitoring Platform to facilitate data collection and increase transparency, and on funding for the work of the steering groups, task force, working parties and expert panels that are to be established.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 129,400+ biopharma pros reading Endpoints daily — and it's free.

Kenneth Galbraith, incoming Zymeworks CEO

Zymeworks re­places half its C-suite, aims to lay off 25% of to­tal work­force as new CEO takes over

New Zymeworks CEO Kenneth Galbraith is aiming to hit the ground running when his tenure officially begins next month, but he’ll be doing so with a much different looking team.

In a lengthy press release outlining the biotech’s 2022 goals, Galbraith said Zymeworks will be laying off at least 25% of its staff over the course of the year. Half of its C-suite will also be replaced immediately as Galbraith looks to remake the company in his image after Ali Tehrani, Zymeworks’ founder and CEO since 2003, stepped down two weeks ago.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 129,400+ biopharma pros reading Endpoints daily — and it's free.

Crit­ics push back on Alzheimer’s As­so­ci­a­tion ad blitz to get Medicare to change its Aduhelm rul­ing: 'Dead wrong'

The latest Alzheimer’s Association advertising campaign encourages people to fight.

Not against the disease or for more research or treatments, but against the Centers for Medicare and Medicaid Services. More specifically, CMS’ recent reimbursement decision to only pay for Biogen and Eisai’s controversial Alzheimer’s drug Aduhelm for patients in clinical trials.

With CMS’ preliminary decision now in a 30-day comment period, patient advocates’ goal is to convince CMS to reverse its decision with a marketing blitz and public pressure.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 129,400+ biopharma pros reading Endpoints daily — and it's free.

Dan O'Day, Gilead CEO (Jim Watson/AFP via Getty Images)

Fail­ing to con­firm clin­i­cal ben­e­fit, Gilead pulls 2 ac­cel­er­at­ed ap­proval in­di­ca­tions for can­cer drug

Gilead recently decided to pull two indications for its cancer drug Zydelig — in relapsed follicular B-cell non-Hodgkin lymphoma (FL) and relapsed small lymphocytic leukemia (SLL) — after failing to complete the confirmatory trials required as part of the accelerated approvals from 2014.

“As the treatment landscape for FL and SLL has evolved, enrollment into the confirmatory study has been an ongoing challenge,” Gilead said in a statement, noting it formally notified the FDA of its decision to voluntarily withdraw these indications.

Richard Pazdur (via AACR)

Time lim­its on ac­cel­er­at­ed ap­provals? FDA's on­col­o­gy chief Rick Paz­dur eyes po­ten­tial re­forms via in­ter­na­tion­al ap­proach­es

The spotlight on the accelerated approval pathway continues to shine bright, with the FDA’s top oncology official writing in an opinion that the pathway may be strengthened with bits and pieces of what other regulators in Europe and elsewhere have done with their expedited approval pathways, such as adding expiration dates for these faster approvals to ensure they confirm clinical benefit in a timely manner.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 129,400+ biopharma pros reading Endpoints daily — and it's free.

Covid-19 roundup: HHS may strug­gle to ab­sorb Op­er­a­tion Warp Speed; Eu­rope has no plans for a fourth vac­cine dose

Operation Warp Speed, perhaps the greatest achievement of the former Trump administration, promptly delivered Covid-19 vaccine supplies nationwide when they became available, thanks to collaborations between HHS and the Department of Defense, while helping to fund and aid the manufacture of billions of doses.

But since the Biden administration took over a year ago, acting FDA commissioner Janet Woodcock transitioned out of her role as the therapeutics lead in Warp Speed, which has been converted into a new operation without the fancy name (now known as the “HHS-DOD COVID-19 Countermeasures Acceleration Group”), and as of the start of 2022, the Department of Defense is no longer helping HHS on the program.

Flori­da man con­vict­ed of fal­si­fy­ing clin­i­cal tri­al re­sults sen­tenced to over 2 years in prison

A Florida man who falsified medical records in connection to clinical trials was sentenced to 30 months in prison in federal court Thursday.

Daniel Tejeda, 35, of Clewiston, was also ordered to pay $2.1 million in restitution. Tejeda was a project manager and study manager for the CRO Tellus Clinical Research, and made it appear that subjects were participating in trials when they weren’t. Two other research workers from Florida were sentenced in the same case in August for 46 and 30 months, respectively.